目前全世界约有1.7亿慢性丙型肝炎病毒(hepatitis C virus，HCV)感染者，基于干扰素α(interferon α，IFN-α)应用的治疗方案仍是治疗HCV感染的主要方法。传统IFN因半衰期短、极易降解、需要反复给药而限制了其在临床上的应用。用聚乙二醇化方法修饰IFN可以延长IFN的半衰期，并已取得很好的结果。有些聚乙二醇IFN已经上市。研究证明，白蛋白-IFN(albinterferon，Alb-IFN)的效果好于聚乙二醇修饰的IFN，值得关注和深入研究。此文就Alb-IFN在丙型肝炎临床研究中的进展作一综述。

 Treatment regimens based on the use of interferon-α(IFN-α) are still the main method of therapy for chronic hepatitis C virus infection,which affects nearly 170 million people worldwide.The clinical applications of conventional IFN are limited due to the short half-life,easy degradation and the need for repeated administration.Modification of IFN with the pegylated method can extend the half-life of IFN,and has achieved good results.Some of pegylated IFN are available in the market.Studies have shown that albinterferon(Alb-IFN) is more effective than pegylated IFN,and it is worthy of close attention and further studies.The progress in Alb-IFN for the treatment of chronic hepatitis C is discussed in this review.